214 related articles for article (PubMed ID: 23417515)
1. Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study.
Suzuki T; Graff-Guerrero A; Uchida H; Remington G; Caravaggio F; Borlido C; Pollock B; Mulsant B; Deluca V; Ismail Z; Mamo D
Psychopharmacology (Berl); 2013 Jul; 228(1):43-51. PubMed ID: 23417515
[TBL] [Abstract][Full Text] [Related]
2. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).
Vernaleken I; Fellows C; Janouschek H; Bröcheler A; Veselinovic T; Landvogt C; Boy C; Buchholz HG; Spreckelmeyer K; Bartenstein P; Cumming P; Hiemke C; Rösch F; Schäfer W; Wong DF; Gründer G
J Clin Psychopharmacol; 2008 Dec; 28(6):608-17. PubMed ID: 19011428
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects.
Arakawa R; Ito H; Takano A; Okumura M; Takahashi H; Takano H; Okubo Y; Suhara T
Psychopharmacology (Berl); 2010 May; 209(4):285-90. PubMed ID: 20349050
[TBL] [Abstract][Full Text] [Related]
4. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
Tateno A; Arakawa R; Okumura M; Fukuta H; Honjo K; Ishihara K; Nakamura H; Kumita S; Okubo Y
J Clin Psychopharmacol; 2013 Apr; 33(2):162-9. PubMed ID: 23422369
[TBL] [Abstract][Full Text] [Related]
5. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
Mamo D; Kapur S; Shammi CM; Papatheodorou G; Mann S; Therrien F; Remington G
Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
[TBL] [Abstract][Full Text] [Related]
6. Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.
Iwata Y; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Plitman E; Chung JK; Mar W; Gerretsen P; Pollock BG; Mulsant BH; Rajji TK; Mamo DC; Graff-Guerrero A
J Clin Psychiatry; 2016 Dec; 77(12):e1557-e1563. PubMed ID: 28086010
[TBL] [Abstract][Full Text] [Related]
7. The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography.
Bench CJ; Lammertsma AA; Grasby PM; Dolan RJ; Warrington SJ; Boyce M; Gunn KP; Brannick LY; Frackowiak RS
Psychopharmacology (Berl); 1996 Mar; 124(1-2):141-7. PubMed ID: 8935809
[TBL] [Abstract][Full Text] [Related]
8. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [
Slifstein M; Abi-Dargham A; Girgis RR; Suckow RF; Cooper TB; Divgi CR; Sokoloff P; Leriche L; Carberry P; Oya S; Joseph SK; Guiraud M; Montagne A; Brunner V; Gaudoux F; Tonner F
Psychopharmacology (Berl); 2020 Feb; 237(2):519-527. PubMed ID: 31773210
[TBL] [Abstract][Full Text] [Related]
9. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.
Girgis RR; Slifstein M; D'Souza D; Lee Y; Periclou A; Ghahramani P; Laszlovszky I; Durgam S; Adham N; Nabulsi N; Huang Y; Carson RE; Kiss B; Kapás M; Abi-Dargham A; Rakhit A
Psychopharmacology (Berl); 2016 Oct; 233(19-20):3503-12. PubMed ID: 27525990
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of dopamine D
Sakayori T; Tateno A; Arakawa R; Kim WC; Okubo Y
Psychopharmacology (Berl); 2021 May; 238(5):1343-1350. PubMed ID: 33180175
[TBL] [Abstract][Full Text] [Related]
11. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
[TBL] [Abstract][Full Text] [Related]
13. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.
Gefvert O; Bergström M; Långström B; Lundberg T; Lindström L; Yates R
Psychopharmacology (Berl); 1998 Jan; 135(2):119-26. PubMed ID: 9497016
[TBL] [Abstract][Full Text] [Related]
14. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.
Arakawa R; Ito H; Takano A; Takahashi H; Morimoto T; Sassa T; Ohta K; Kato M; Okubo Y; Suhara T
Psychopharmacology (Berl); 2008 Apr; 197(2):229-35. PubMed ID: 18058087
[TBL] [Abstract][Full Text] [Related]
15. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
[TBL] [Abstract][Full Text] [Related]
16. Striatal and extrastriatal dopamine D₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹C]raclopride and [¹¹C]FLB457.
Takahata K; Ito H; Takano H; Arakawa R; Fujiwara H; Kimura Y; Kodaka F; Sasaki T; Nogami T; Suzuki M; Nagashima T; Shimada H; Kato M; Mimura M; Suhara T
Psychopharmacology (Berl); 2012 Jul; 222(1):165-72. PubMed ID: 22237854
[TBL] [Abstract][Full Text] [Related]
17. D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection.
Schmidt ME; de Boer P; Andrews R; Neyens M; Rossenu S; William Falteos D; Mannaert E
Psychopharmacology (Berl); 2012 Dec; 224(4):549-57. PubMed ID: 22773165
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotic-associated mental side effects and their relationship to dopamine D2 receptor occupancy in striatal subdivisions: a high-resolution PET study with [11C]raclopride.
Kim JH; Son YD; Kim HK; Lee SY; Cho SE; Kim YB; Cho ZH
J Clin Psychopharmacol; 2011 Aug; 31(4):507-11. PubMed ID: 21694619
[TBL] [Abstract][Full Text] [Related]
19. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.
Graff-Guerrero A; Mamo D; Shammi CM; Mizrahi R; Marcon H; Barsoum P; Rusjan P; Houle S; Wilson AA; Kapur S
Arch Gen Psychiatry; 2009 Jun; 66(6):606-15. PubMed ID: 19487625
[TBL] [Abstract][Full Text] [Related]
20. The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an [(11)C]raclopride PET study in healthy human subjects.
Tolboom N; Berendse HW; Leysen JE; Yaqub M; van Berckel BN; Schuit RC; Ponsen MM; Bakker E; Hoetjes NJ; Windhorst AD; Carlsson ML; Lammertsma AA; Carlsson A
Neuropsychopharmacology; 2015 Jan; 40(2):472-9. PubMed ID: 25248987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
